about us

We are an oncology company focused on the clinical development of novel therapies for cancer. Our lead programs include a potential best-in-class HDAC inhibitor, Pracinostat, a novel mitochondrial inhibitor, ME-344, and a PI3-kinase delta inhibitor, PWT143.
[ Read more ]

latest news

MEI Pharma Adds David Urso as Senior Vice President of Corporate Development and General Counsel
[ April 8, 2014 ]

MEI Pharma Identifies Potential Biomarker for Pracinostat in Bladder Cancer (AACR)
[ April 7, 2014 ] [ Poster ]

MEI Pharma to Present at Needham Healthcare Conference on April 8th
[ April 1, 2014 ] [ Webcast ]

MEI Pharma Receives Orphan Status for Pracinostat for Treatment of AML
[ February 28, 2014 ]

Annual Review Cover
Click here for our 2013 Annual Review